James Hu, MD
Medical Oncology · Los Angeles, CANPI 1467424929
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,918 of the $17,420 with a category attached, or 62.7%. Springworks Therapeutics, Inc. accounts for 82.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $12,280 and has fallen 70.5% since, to $3,622 in 2025.
Across 97 payments — averaging $179.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Springworks Therapeutics, Inc.$14K
- W. L. Gore & Associates, Inc.$816
- Aadi Bioscience, Inc.$400
- F. Hoffmann-la Roche AG$243
- Exelixis Inc.$196
- Johnson & Johnson$181
- plus $1K from 19 others
Across 147 payments — averaging $4302.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$320K
- Sumitomo Pharma America, Inc.$116K
- Daiichi Sankyo Inc.$69K
- AbbVie$35K
- Servier Bioinnovation$27K
- Eli Lilly$23K
- plus $43K from 5 others
What the payments were for
- Consulting fees$2,80016%
- Speaking & faculty fees$10,91863%
- Travel & lodging$5233%
- Food & beverage$3,15018%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Springworks Therapeutics, Inc. | 19 | $14,357 |
| W. L. Gore & Associates, Inc. | 8 | $816 |
| Aadi Bioscience, Inc. | 11 | $400 |
| F. Hoffmann-la Roche AG | 1 | $243 |
| Exelixis Inc. | 8 | $196 |
| Johnson & Johnson(3 entities) | 6 | $181 |
| Merck | 3 | $145 |
| Incyte Corporation | 5 | $125 |
| Siemens Medical Solutions USA, Inc. | 1 | $115 |
| Bayer | 7 | $108 |
| Deciphera Pharmaceuticals Inc. | 4 | $102 |
| Progenics Pharmaceuticals, Inc. | 1 | $94 |
| Amgen | 4 | $81 |
| Caris MPI, Inc. | 2 | $71 |
| AstraZeneca(2 entities) | 3 | $71 |
| Pfizer | 3 | $54 |
| Baxter Healthcare | 1 | $46 |
| Lilly USA, LLC | 2 | $36 |
| Astellas Pharma US Inc | 1 | $34 |
| Puma Biotechnology, Inc. | 2 | $34 |
| Tempus AI, Inc | 1 | $27 |
| Flowonix Medical Incorporated | 1 | $23 |
| Bristol Myers Squibb | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OGSIVEO$14,164
- GORE EXCLUDER AAA Endoprosthesis$546
- Non-Covered Product$243
- FYARRO$239
- Varian CRYOCARE TOUCH System$115
How this compares
$17,420 in reported general payments places this provider in the 65th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Los Angeles
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
- Mark AgulnikLos Angeles$303K
- Heinz-Josef LenzLos Angeles$185K
- Syma IqbalLos Angeles$178K
- Anthony El-KhoueiryLos Angeles$156K
- David QuinnLos Angeles$134K
- David TranLos Angeles$128K
- Afsaneh BarziLos Angeles$107K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.